Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of HCP1801 in Healthy Subjects
NCT03826641Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of Dapagliflozin at 48 hours, Area Under the Curve to the Last Measurable Concentration (AUClast) of Dapagliflozin at 48 hours and 2 more. Started Feb 2019; status: completed.
02
Drugs
dapagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03826641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826641.